Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Reaffirmed as "Buy" by HC Wainwright

Prelude Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reaffirmed its Buy rating on Prelude Therapeutics and maintained an $8 price target, implying roughly 141% upside from the stock’s current price.
  • Analyst views are mixed, but MarketBeat’s consensus is Moderate Buy with an average price target of $8.75; five analysts rate it Buy, one Hold, and one Sell.
  • Prelude reported a quarterly loss of $0.12 per share, missing the $0.01 consensus estimate, and revenue of $5.65 million versus expectations of $29 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 140.96% from the stock's current price.

PRLD has been the subject of several other research reports. JPMorgan Chase & Co. began coverage on Prelude Therapeutics in a report on Thursday, September 17th. They set an "overweight" rating and a $12.00 price objective for the company. Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, September 19th. Citigroup reissued a "market outperform" rating on shares of Prelude Therapeutics in a research report on Wednesday, October 14th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Prelude Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

Check Out Our Latest Stock Analysis on Prelude Therapeutics

Prelude Therapeutics Trading Down 2.6%

Shares of NASDAQ PRLD opened at $3.32 on Wednesday. The firm has a market capitalization of $264.94 million, a P/E ratio of -5.63 and a beta of 1.22. The firm's 50-day moving average price is $3.92 and its 200-day moving average price is $4.08. Prelude Therapeutics has a 1-year low of $1.29 and a 1-year high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.13). The firm had revenue of $5.65 million during the quarter, compared to the consensus estimate of $29.00 million. Equities research analysts forecast that Prelude Therapeutics will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Spark Investment Management LLC purchased a new stake in shares of Prelude Therapeutics in the second quarter valued at about $56,000. GSA Capital Partners LLP bought a new stake in Prelude Therapeutics in the 2nd quarter worth about $68,000. Hsbc Holdings PLC purchased a new stake in Prelude Therapeutics in the 2nd quarter valued at about $74,000. Polymer Capital Management US LLC purchased a new stake in Prelude Therapeutics in the 3rd quarter valued at about $55,000. Finally, Bank of America Corp DE purchased a new stake in Prelude Therapeutics in the 2nd quarter valued at about $127,000. Hedge funds and other institutional investors own 79.72% of the company's stock.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude's pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Further Reading

Analyst Recommendations for Prelude Therapeutics (NASDAQ:PRLD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prelude Therapeutics Right Now?

Before you consider Prelude Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.

While Prelude Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines